InvestorsHub Logo
Followers 3
Posts 288
Boards Moderated 0
Alias Born 12/21/2022

Re: None

Monday, 02/27/2023 9:22:53 AM

Monday, February 27, 2023 9:22:53 AM

Post# of 3283
$100M this year, how about that?
US sales of Hanmi Pharmaceutical Co.’s Rolvedon (eflapegrastim-xnst), a drug used to reduce the incidence of infection as manifested by febrile neutropenia in adult patients with non-myeloid malignancies, topped $10 million just three months after its launch in the US by Spectrum Pharmaceuticals Inc. The US partner projected its sales would reach $100 million this year.
https://www.kedglobal.com/bio-pharma/newsView/ked202302270012